A Prospective, Observational, Open-Label, Multicenter Study Evaluating the Safety, Tolerability, Adherence and Efficacy of Tenofovir/Emtricitabine/Rilpivirine (TDF/FTC/RPV) in HIV Post-Exposure Prophylaxis (PEP)

Trial Profile

A Prospective, Observational, Open-Label, Multicenter Study Evaluating the Safety, Tolerability, Adherence and Efficacy of Tenofovir/Emtricitabine/Rilpivirine (TDF/FTC/RPV) in HIV Post-Exposure Prophylaxis (PEP)

Completed
Phase of Trial: Phase IV

Latest Information Update: 27 Oct 2017

At a glance

  • Drugs Emtricitabine/rilpivirine/tenofovir disoproxil fumarate (Primary)
  • Indications HIV infections
  • Focus Adverse reactions; Pharmacodynamics; Therapeutic Use
  • Most Recent Events

    • 27 Oct 2017 Status changed from recruiting to completed, according to the final results presented at the 16th European AIDS Conference.
    • 27 Oct 2017 Final results presented at the 16th European AIDS Conference.
    • 30 Aug 2017 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top